Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

Strumberg, Dirk; W. Clark, Jeffrey; Awada, Ahmad; J. Moore, Malcolm; Richly, Heike; Hendlisz, Alain; W. Hirte, Hal; P. Eder, Joseph; Lenz, Heinz-Josef; Schwartz, Brian

doi:10.1634/theoncologist.12-4-426

Public

Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors

Shared by NobleBlocks on Apr 1, 2007 • 12:00 AM UTC

Authors:

Dirk Strumberg

Jeffrey W. Clark

Ahmad Awada

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the mechanisms of action of sorafenib.Discuss the safety and toxicity data from phase I trials of sorafenib.Evaluate phase I and II trials of sorafenib with activity data.Discuss future areas for research in the d...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!